A report from EuroEFE / EURACTIV it deals with the damage caused by the low prices of generic and biosimilar medicines in an environment of high inflation, and proposes ideas to make it easier for their contribution to the sustainability of the health system to remain relevant and continuous. In the report participates with her opinion the general director of BioSim, encarna cruz.
recently published
Horizon scanning
Jan 31 2024
Early Treatment: the role of biosimilars
18 2023 December
